Key Drivers
- Strong Liquidity
- Persistent Losses
- Rising Debt
AIAI Summary
CAPR is now a high-risk regulatory-credibility trade: Deramiocel's upside depends less on clinical promise than on transparent evidence and FDA acceptance of protocol and blinding practices, so investors should await clear regulatory validation before treating the cash-backed valuation as a durable floor.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Rising Debt
CAPR has strong near-term liquidity and trades near tangible book value, but persistent losses, heavy cash burn, rising debt, and reliance on equity financing make it a high-risk investment.
Price Behavior
Key Price Behavior Insights:
- •Recovery intact
- •Volatile consolidation
- •Breakout needed
CAPR remains constructive above $8.30–$8.60 but needs a decisive break over $10.10 to resume upside amid volatile, weak-to-neutral momentum.
Sharp rebound from $6.29 to $10.06 in late
Sentiment & News
Key News Insights:
- •FDA Disclosure Concerns
- •Sharp Share Decline
- •Investor Litigation
Capricor faces significant downside risk as FDA disclosure concerns triggered a steep selloff and expanding shareholder litigation.
The litigation and regulatory uncertainty are likely to sustain pressure on CAPR shares until clearer FDA and company communications emerge
Similar Companies in Healthcare
Other companies in the same sector with AI ratings